FDA Approves Monthly Dosing of Amivantamab for EGFR-Mutated NSCLC

The Food and Drug Administration (FDA) has approved a simplified monthly dosing schedule for amivantamab-vmjw (Rybrevant Faspro) in combination with lazertinib (Lazcluze) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This approval applies to patients whose tumors harbor EGFR exon 19 deletions or exon 21 L858R substitution mutations.

Reducing Treatment Burden for NSCLC Patients

Previously approved in December for biweekly subcutaneous injection, amivantamab has now demonstrated similar efficacy and safety with a monthly administration schedule Medscape. This change aims to reduce clinic visit frequency and potentially decrease infusion-related reactions, improving the patient experience.

How the New Regimen Works

The approved regimen involves monthly subcutaneous amivantamab plus oral lazertinib. This combination therapy offers a new option for patients with EGFR-mutated advanced NSCLC, a challenging subtype of the disease. Targeted Oncology

Efficacy and Safety Profile

Clinical trials have shown that the monthly dosing schedule maintains the efficacy and safety profile established with the biweekly injections. The approval allows for a reduction in clinic visits without compromising treatment outcomes. AJMC

What is EGFR-Mutated NSCLC?

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. Approximately 10-15% of NSCLC cases have mutations in the epidermal growth factor receptor (EGFR) gene. These mutations can drive cancer growth, but also make the cancer susceptible to targeted therapies like amivantamab and lazertinib. OncNursing News

Key Takeaways

• The FDA has approved monthly subcutaneous amivantamab in combination with lazertinib for EGFR-mutated NSCLC.
• This new schedule reduces the frequency of clinic visits for patients.
• The monthly dosing maintains the established efficacy and safety profile.
• This approval provides a more convenient treatment option for patients with this specific type of lung cancer.